Pay in 4 interest-free payments of $5.38 Learn more
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28
Triple-hormone-receptor agonist Retatrutide for obesity: Phase 2 trial (48-week study, up to 24% weight loss) American Diabetes Association (2023) ADA Press Release: Novel agent Retatrutide results in substantial weight reduction (83rd Scientific Sessions, Phase 2 data) ADA Meeting News (2023) Phase 2 trial results: benefits of Retatrutide in obesity, type 2 diabetes, NASH (83rd ADA Scientific Sessions coverage) ClinicalTrials.gov Study of Retatrutide (LY3437943) in adults with obesity (NCT04881760
Kisli M, Sacmaci H
The full dose is delivered straight into your system, enabling you to feel happier, vibrant and more energised
Quality and Sourcing All recovery peptides from Durham Peptides are independently tested by Janoshik Analytical with verifiable COAs
